

#### MULTI-REGIONAL CLINICAL TRIALS

THE MRCT CENTER of BRIGHAM AND WOMEN'S HOSPITAL and HARVARD

## Achieving Diversity, Inclusion, Equity In Clinical Research

Monday, October 19, 2020

#### Barbara E. Bierer, MD

Professor of Medicine, Harvard Medical School Faculty Director, MRCT Center of BWH & Harvard bbierer@bwh.harvard.edu

#### Disclaimer

The views and findings expressed in this document are those of the authors and do not imply endorsement or reflect the views or policies of the U.S. Food and Drug Administration or the affiliated organization or entity of any member who contributed to this work. Individuals have served in their individual capacity.

The MRCT Center is supported by voluntary contributions (<u>www.MRCTCenter.org</u>) and grants.



#### Today's Agenda

- MRCT Center introduction
- Introduction to Achieving Diversity, Inclusion, Equity In Clinical Research Guidance Document
- Presentations by:
  - o Paul Underwood, M.D., FACC, FSCAI
  - o Eldrin Lewis, M.D., MPH



### The Multi-Regional Clinical Trials Center (MRCT Center)

#### **Our Vision**

Improve the integrity, safety, and rigor of global clinical trials.

#### **Our Mission**

Engage diverse stakeholders to define emerging issues in global clinical trials and to create and implement ethical, actionable, and practical solutions.





### **Addressing the pressing issues of MRCTs**



REGULATORY

ENGAGEMENT



OVERSIGHT

CONDUCT, AND



TRANSPARENCY





#### **Recognizing the need to focus on and with the** participant

- Post trial access to medicines
- Return of Results
- Health Literacy
- Diversity, Inclusion, Equity



Join us:



### MULTI-REGIONAL CLINICAL TRIALS

THE MRCT CENTER of BRIGHAM AND WOMEN'S HOSPITAL and HARVARD



MRCTcenter.org








19 October 2020 Ropes & Gray

©MRCT Center

mrctcenter.org/diversity-in-clinical-trials

### Health disparities by race and ethnicity in the COVID-19 pandemic

#### Adjusted for age, race and ethnicity widens the gap in mortality compared to Whites



#### But are underrepresented in research



The NEW ENGLAND JOURNAL of MEDICINE



#### **Racial Disproportionality in Covid Clinical Trials**

Daniel B. Chastain, Pharm.D., Sharmon P. Osae, Pharm.D., Andrés F. Henao-Martínez, M.D., Carlos Franco-Paredes, M.D., M.P.H., Joeanna S. Chastain, Pharm.D., and Henry N. Young, Ph.D. **News & Analysis** 

#### **Medical News & Perspectives**


Researchers Strive to Recruit Hard-Hit Minorities Into COVID-19 Vaccine Trials

#### Mary Chris Jaklevic, MSJ

https://jamanetwork.com/journals/jama/fullarticle/2769611



#### Drug Trial Snapshots: Summaries



©MRCT Center

### Background

- Clinical trials are needed to develop new treatments and new vaccines.
- Participants in trials should reflect the population affected by the disease, or those intended to utilize the intervention.
- We should not assume that all individuals respond similarly to interventions.
- Underrepresentation in clinical trials of Black, Latinx, Asian, Native American, and other underserved populations—as well as women and individuals at either end of the age spectrum—is not new, and persists in both industry and academic trials, and across therapeutic areas.
- Race and ethnicity are not a biological determinants; and social determinants of health have a real impact on biology.
- Diverse representation in clinical trials is not simply a matter of biology, but a matter of health equity, fairness, and public trust.



#### Leadership

- RADM Richardae Araojo, PharmD, MS, U.S. FDA
- Barbara E. Bierer, MD, MRCT Center
- Luther T. Clark, MD, Merck & Co., Inc.
- Milena Lolic, MD, U.S. FDA
- David H. Strauss, MD, Columbia University
- Sarah White, MPH, MRCT Center

#### MRCT Center staff:

- Carmen Aldinger, PhD, MPH
- Hayat Ahmed, MS
- Laura Meloney, MS, MPH
- Joshua Smith-Sreen, MBE

And the invaluable contributions of >50 workgroup members, representing:

- Patients, Patient Advocates
- Academia
- Pharmaceutical companies
- CROs
- Non-profit organizations
- Trade associations
- Government agencies
- Research institutes

Each serving in their individual capacity.



#### MRCT Diversity Workgroup

Maria Apostolaros, PhRMA Abhijit Bapat \*, Novartis Stacey Bledsoe\*, Eli Lilly and Company Shari Bodnoff\*, Novartis Racquel Bruton, Biogen Elizabeth Cahn, Cancer Connection Li Chen, Amgen Patrick Cullinan, Takeda, currently BlueBird Bio Liza Dawson\*, National Institutes of Health (NIH) Maria De Leon\*, Parkinson's Foundation Theresa Devins, Boehringer Ingelheim, currently Regeneron Pharmaceuticals Anthony Edmonds, Takeda Rhona Facile, Clinical Data Interchange Standards Consortium (CDISC) Rachael Fones, IQVIA Laura Gordon\*, Institute for Advanced Clinical Trials for Children (iACT) Anya Harry, GlaxoSmithKline (GSK) Melissa Heidelberg, Genentech/ A Member of the Roche Group Quita Highsmith, Genentech/ A Member of the Roche Group Sharareh Hosseinzadeh, Novartis Lloryn Hubbard\*, Genentech/ A Member of the Roche Group Anne Marie Inglis\*, GlaxoSmithKline (GSK), currently Mallinckrodt Pharmaceuticals Aarthi B. Iyer\*, Kinetig, now Advarra Becky Johnson\*, IQVIA Tesheia Johnson, Yale School of Medicine Jonathan Jackson\*, Massachusetts General Hospital Marcia Levenstein, Vivli Roberto Lewis, Columbia University Eldrin Lewis, Brigham and Women's Hospital, currently Stanford University

\*involvement limited in time

Jianchang Lin\*, Takeda Erin Muhlbradt, National Cancer Institute (NCI) Isabela Niculae\*, Biogen Latha Palaniappan, Stanford University Claude Petit, Boehringer Ingelheim Claire Pigula\*, Biogen Melissa Poindexter\*, Advances in Health Nicole Richie, Genentech/ A Member of the Roche Group Bryant (Abel) Riera\*, Population Council Suzanne M. Rivera, Case Western Reserve University Frank W. Rockhold, Duke University Ricardo Rojo\*, Pfizer Rosanne Rotondo\*, Novartis Fabian Sandoval, Emerson Clinical Research Institute Richard Sax\*, IQVIA Hollie Schmidt, Accelerated Cure Project for Multiple Sclerosis Karlin Schroeder, Parkinson's Foundation Mary Scroggins\*, Pinkie Hugs Jessica Scott\*, Takeda Lana Skirboll, Sanofi Steven Snapinn, Seattle- Quilcene Biostatistics Stacey Springs\*, Harvard Medical School Sara Tadesse-Bell, Genentech/ A Member of the Roche Group Ann Taylor\*, Columbia University Paul Underwood, Boston Scientific Junyang Wang, Food and Drug Administration (FDA) Robert Winn\*, University of Illinois Gerren Wilson\*, Genentech/ A Member of the Roche Group Crispin Woolston, Sanofi Honghui Zhou\*, Johnson & Johnson




MULTI-REGIONAL CLINICAL TRIALS THE MRCT CENTER OF BRIGHAM AND WOMEN'S HOSPITAL and HARVARD

#### ACHIEVING DIVERSITY, INCLUSION, AND EQUITY IN CLINICAL RESEARCH

**Guidance Document** 





Achieving Diversity, Inclusion, Equity In Clinical Research

> Guidance and Toolkit Released 6 August 2020

#### mrctcenter.org/diversity-in-clinical-trials



12

### It starts with evidence, information, and trust

- Data must include those populations affected.
- It starts with public and community engagement.
- Clinical trials should:
  - o address questions of importance to the community
  - be designed with study outcomes that people care about
  - use language and words that people understand
  - be conducted in ways that decrease burden for the participants, and
  - communicate results to the communities affected.
- We should hold each other accountable at every stage.



### Sections of the Guidance Document


- Preface
- Part A Building the Case
- Part B Background, Ethical Principles, and Regulatory Directives
- Part C Broadening Engagement
- Part D Data Standards and Analysis
- Part E Study Design, Conduct, and Implementation
- Part F Stakeholder Commitments and the Future
- Part G Appendix


#### Toolkit



### Diversity exists across many dimensions

#### A broad definition of diversity






#### Intersectionality:

• Dimensions of diversity are not independent variables



#### Barriers: Every stakeholder has responsibility



#### Individuals must be invited





19 October 2020 Ropes & Gray

#### Patient and community engagement support diverse participation

Forming Relationships The patient and community to be in key leadership roles, as advisors, and as consultants.

Sustained partnerships



**Build Trust** 



18


Training and Support Patient perspective to influence research priorities and questions

#### Shared Goals

Seek input to tailor study design and conduct to improve access, enrollment, and retention

19 October 2020 Ropes & Gray

#### Participant's Clinical Trial Journey




#### STUDY LEVEL DIVERSITY CONSIDERATIONS



©MRCT Center


#### Product Development Pathway





©MRCT Center

### Clear communications throughout the product development program



#### Clear communication is a shared responsibility



- Plain language
- Numeracy
- Visualization
- Clear design
- Cultural considerations
- Interactive techniques
- Teach-back

- It is not that the listener has "poor literacy."
- The communicator is responsible for sharing information that is understandable to the listener.
- The listener should be comfortable communicating any lack of understanding



Written Materials Verbal Communications




### The MRCT Center launched a "Health Literacy in Clinical Research" website





In a language understandable to the participant

#### **Tools and Resources**





www.mrctcenter.org/health-literacy



19 October 2020 Ropes & Gray


©MRCT Center

#### **COVID-19** Research Flyers

### "Should I join?"

#### Resources for the public

https://mrctcenter.org/blog/reso urces/covid-19-clinical-researchflyers/



#### En Español

#### ¿Debería unirme?





24

19 October 2020 Ropes & Gray

#### Opportunities: What can we do?

		<ul> <li>Determine access to potential target population to guide country, region, and site selection</li> <li>Use data-driven strategies</li> <li>Determine the feasibility of enrollment figures for target subpopulations in partnership with site(s)</li> </ul>		<ul> <li>Ensure recruitment strategy is informed by patient preferences</li> <li>Connect with referral networks in the community, including organizations directly involved with target population</li> <li>Monitor and communicate site progress, address and adjust with site as needed</li> </ul>
	Trial Design	Site Selection	Site Support & Communication	Accountability
19 October 2020	<ul> <li>Characterize target population based on epidemiology, disease burden and demographics</li> <li>Engage patient population to maximize recruitment and retention strategies and minimize burden of trial</li> </ul>	©MRCT Center	<ul> <li>Communicate targets for enrollment including demographic projections</li> <li>Assist sites with local recruitment plan and outreach activities</li> <li>Assess and support each site's cultural readiness</li> <li>Provide diversity training to Investigators and site staff</li> </ul>	25

### Solve for logistical challenges

- Easy and quick reimbursement processes
- Consider compensation for missed work or caregiver support
- Flexible, extended site hours (after work hours and weekends)
- Flexible appointments
- On-site childcare and eldercare
- Provide transportation or assist with arrangements
- Health literate study information in the correct language
- Culturally competent and linguistically-capable staff



### Key Opportunities & Future Actions

- Patient and Community Awareness, Access, Engagement, and Participation; Trust, Trustworthiness
- Workforce Diversity
- Eligibility and Study Design
- Logistics and Flexibility
- Data Standards and Analyses
- Innovation
- Genetics
- Diversity in data sources and databases; RWE

**L** Is there anything that we should understand to make your participation easier?

#### Accountability in Partnership



# Holding ourselves and one another accountable

- Metrics
- Transparency
- Dialogue



#### The work ahead

- What can each of us do now?
  - One step at a time towards change
- Targeted recommendations for special populations
- Additional tools and resources
- Need for local, national, and international focus going forward
- Committing to inclusion is our first step.

"...the real work of change is done year by year, month by month, and day by day, by all of us, by each of us..."

mrctcenter.org/diversity-in-clinical-trials





Wednesdays 11AM -12noon ET



**LEANING IN: A WEBINAR SERIES** 

October 14, 2020	Community Awareness, Access, Knowledge		
October 28, 2020	Workforce Development		
November 11, 2020	Study Design, Eligibility, Site Selection & Feasibility		
December 9, 2020	Study Conduct (Recruitment, Retention)		


January 13, 2021 Data Standards and Analysis

January 27, 2021 Stakeholder Roles and Responsibilities

February 10, 2021Role of Data in Diversity: Genetics & Real World Data



#### Today's speakers



No slides, Please listen to the webinar

#### Paul Underwood, M.D., FACC, FSCAI

Medical Director, Close the Gap and Interventional Cardiology Boston Scientific



#### Today's speakers



#### Eldrin Lewis, M.D., MPH

Professor of Medicine, Stanford Medicine



# Achieving Diversity, Inclusion, and Equity in Clinical Research

Eldrin Lewis, MD, MPH, FAHA, FACC Professor of Medicine Chief, Cardiovascular Medicine Stanford University

October 19, 2020



Stanford MEDICINE

# **Faculty Disclosures**

- Novartis (Consulting, Institutional research support)
- NHLBI (Institutional research support)
- Sanofi (Institutional research support)
- Merck (Consulting, Institutional research support)
- DalCor (Consulting)

# Outline

- Brief history/intro, entry into current work
- Perspective as an investigator for site activities to increase diversity
- Experience in workforce development for diversity and inclusion
- Any relevant success stories or lessons learned

# **My Journey: Training and Education**









# My Journey: Training and Education and Practice



- CV Clerkship director
- Recruitment
- STARS program







#### HARVARD BUSINESS SCHOOL

Executive Education

#### Scientific Interest and Mission

**Research Mission:** To improve outcomes in patients with heart failure and at risk for CVD

Prevention	Treatment/Efficacy	Outcomes			
-Diabetes mellitus -Chronic kidney disease -Sleep apnea -Hypertension	-Heart failure -CAD -Myocardial infarction -Sleep apnea	-CV morbidity -Mortality -Quality of life			
	Quality of life				
Randomized Clinical Trials					
	Management strategies				
	Disparities and Health Equity				

## Outline


- Brief history/intro, entry into current work
- Perspective as an investigator for site activities to increase diversity
- Experience in workforce development for diversity and inclusion
- Any relevant success stories or lessons learned


#### Perspective as an Investigator for Site Activities to Increase Diversity


Active	Tear		Tracking	Set New
recruitment	Buildi		Metrics	Norms
<ul> <li>Develop strategies</li> <li>Evaluate commitments</li> <li>Recruitment materials</li> <li>Patient and community groups</li> </ul>	<ul> <li>CRAs</li> <li>Partner faculty</li> <li>Organiza</li> </ul>	-One size does	-Set expectations	- Expectations - "Can mentality"


## Outline


- Brief history/intro, entry into current work
- Perspective as an investigator for site activities to increase diversity
- Experience in workforce development for diversity and inclusion
- Any relevant success stories or lessons learned











## Outline

- Brief history/intro, entry into current work
- Perspective as an investigator for site activities to increase diversity
- Experience in workforce development for diversity and inclusion
- Any relevant success stories or lessons learned

#### Conclusions

- Diverse workforce can enrich clinical research enterprise
- Need extended pipelines and training
- Diversity training and leadership training paramount
- Involving community groups can allow shared vision for enrolling patients into clinical studies



#### Eldrin F. Lewis, MD, MPH, FAHA, FACC

Professor of Medicine Chief, Division of Cardiovascular Medicine Advanced Heart Failure Transplant Cardiology Stanford University School of Medicine <u>eflewisi@Stanford.edu</u>

#### Stanford University